Protocol Ledger

NCT05018221 · Phase III · RECRUITING

Better Evidence and Translation for Calciphylaxis

Interventional Phase III clinical trial protocol NCT05018221 sponsored by University of Sydney in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-26 Enrollment: 350 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05018221
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05018221
Protocol FieldVerified Registry Value
NCT IdentifierNCT05018221
Consolidated Lead SponsorUniversity of Sydney
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment350 participants (ESTIMATED)
Registered Start Date2021-08-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05018221
Hospital Research SiteLocationSite Profile
Concord Repatriation General HospitalConcord, AustraliaOpen Hospital Dossier ->
Liverpool HospitalLiverpool, AustraliaOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI